Veterinary Medicines

Bovilis IBR marker live, lyophilisate and solvent for suspension for cattle

Authorised
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Download as PDF

Product identification

Medicine name:
Bovilis IBR marker live, lyophilisate and solvent for suspension for cattle
Active substance:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Target species:
  • Cattle
Route of administration:
  • Nasal use
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
    7.30
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Nasal use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
  • Intramuscular use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD01
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (100 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (10 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (20 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 PET vials of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (5 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (25 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 glass vial (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 PET vial of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (5 doses) and 1 glass vial (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (25 doses) and 1 glass vial (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (100 doses) and 1 glass vial (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (10 doses) and 1 glass vial (hydrolytic type II) of solvent (20 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Intervet (Ireland) Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10996/172/001
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0105/001
Concerned member states:
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."